Immunovant, Inc. (IMVT)
28.68
+0.51
(+1.81%)
USD |
NASDAQ |
Oct 27, 11:31
Immunovant Market Cap : 5.916B for Oct. 27, 2026
Market Cap Chart
Historical Market Cap Data
| Date | Value |
|---|---|
| October 26, 2026 | 5.810B |
| October 23, 2026 | 5.860B |
| October 22, 2026 | 6.002B |
| October 21, 2026 | 5.854B |
| October 20, 2026 | 5.897B |
| October 19, 2026 | 5.697B |
| October 16, 2026 | 5.513B |
| October 15, 2026 | 5.674B |
| October 14, 2026 | 5.755B |
| October 13, 2026 | 5.922B |
| October 12, 2026 | 6.081B |
| October 09, 2026 | 6.285B |
| October 08, 2026 | 6.242B |
| October 07, 2026 | 6.609B |
| October 06, 2026 | 6.623B |
| October 05, 2026 | 6.858B |
| October 02, 2026 | 6.935B |
| October 01, 2026 | 6.941B |
| September 30, 2026 | 6.968B |
| September 29, 2026 | 6.902B |
| September 28, 2026 | 6.908B |
| September 25, 2026 | 6.869B |
| September 24, 2026 | 7.013B |
| September 23, 2026 | 7.124B |
| September 22, 2026 | 7.692B |
| Date | Value |
|---|---|
| September 21, 2026 | 7.669B |
| September 18, 2026 | 7.621B |
| September 17, 2026 | 7.766B |
| September 16, 2026 | 7.504B |
| September 15, 2026 | 7.560B |
| September 14, 2026 | 7.768B |
| September 11, 2026 | 7.706B |
| September 10, 2026 | 7.859B |
| September 09, 2026 | 7.993B |
| September 08, 2026 | 8.162B |
| September 04, 2026 | 8.096B |
| September 03, 2026 | 8.069B |
| September 02, 2026 | 8.145B |
| September 01, 2026 | 8.230B |
| August 31, 2026 | 8.420B |
| August 28, 2026 | 8.498B |
| August 27, 2026 | 9.039B |
| August 26, 2026 | 9.053B |
| August 25, 2026 | 8.973B |
| August 24, 2026 | 8.935B |
| August 21, 2026 | 9.152B |
| August 20, 2026 | 9.148B |
| August 19, 2026 | 9.274B |
| August 18, 2026 | 9.138B |
| August 17, 2026 | 9.016B |
Market Capitalization Definition
Market Capitalization measures the total value of a company based on their stock price multiplied by the shares outstanding. This metric is important because it gives you an idea of the size of a company, and how the size has changed over time. When studying companies from a relative basis, it would make sense to compare companies that have a similar market capitalization because factors like market share, economies of scale, and business models would also be similar.
Market Cap Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Market Cap Benchmarks
| Roivant Sciences Ltd. | 26.41B |
| Moderna, Inc. | 77.15B |
| Altimmune, Inc. | 408.40M |
| Vertex Pharmaceuticals, Inc. | 130.49B |
| First Tracks Biotherapeutics, Inc. | 1.608B |
Market Cap Related Metrics
| Price to Book Value | 8.044 |
| Price | 28.68 |
| Earnings Yield | -9.79% |